内容紹介
Summary
In this study, 97 cancer patients were treated with combined immune checkpoint inhibitor therapy and dendritic cell therapy between June 2015 and April 2018. We administered nivolumab with 2-3 mg/kg bw every 2-3 weeks. The rate of progress in cases where nivolumab was administered more than 3 times was 55.2%. Dendritic cell therapy enhanced the immune checkpoint inhibitor therapy. In cases where the effect of combined immune checkpoint inhibitor therapy and dendritic cell therapy was restricted, hyperthermia and radiation therapy are useful for the recovery of combined therapy. Key words: Immune checkpoint inhibitor, Hyperthermia, Dendritic cell
要旨
2015年6月～2018年4月に,97例の悪性腫瘍に樹状細胞と免疫チェックポイント阻害薬の併用投与を施行した。3回以上投与した症例の有効率は55.2%であった。免疫チェックポイント阻害薬の効果増強には樹状細胞療法の併用が重要であり,それに加えて温熱療法,放射線の併用も有効であった。
目次
In this study, 97 cancer patients were treated with combined immune checkpoint inhibitor therapy and dendritic cell therapy between June 2015 and April 2018. We administered nivolumab with 2-3 mg/kg bw every 2-3 weeks. The rate of progress in cases where nivolumab was administered more than 3 times was 55.2%. Dendritic cell therapy enhanced the immune checkpoint inhibitor therapy. In cases where the effect of combined immune checkpoint inhibitor therapy and dendritic cell therapy was restricted, hyperthermia and radiation therapy are useful for the recovery of combined therapy. Key words: Immune checkpoint inhibitor, Hyperthermia, Dendritic cell
要旨
2015年6月～2018年4月に,97例の悪性腫瘍に樹状細胞と免疫チェックポイント阻害薬の併用投与を施行した。3回以上投与した症例の有効率は55.2%であった。免疫チェックポイント阻害薬の効果増強には樹状細胞療法の併用が重要であり,それに加えて温熱療法,放射線の併用も有効であった。